Breakfast symposium: From hospital to home - the focus on the patient

Similar documents
Service Specification Template Department of Health, updated June 2015

Dorset Cardiac Centre

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Introduction. Background to this event. Raising awareness 09/11/2015

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

How To Treat Aneuricaagulation

Bridging the Gap: How to Transition from the NOACs to Warfarin

An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban)

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

S1. Which of the following age categories do you fall into? Please select one answer only years of age years of age years of age

Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid

STROKE PREVENTION IN ATRIAL FIBRILLATION

9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?

Keeping patients safe when they transfer between care providers getting the medicines right

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Title Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist.

Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

9/5/14. Objectives. Atrial Fibrillation (AF)

NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

Novel Oral Anticoagulants (NOACs) Prescriber Update 2013

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

New Oral Anticoagulant Drugs What monitoring if any is required?

Rx Updates New Guidelines, New Medications What You Need to Know

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Commissioning effective anticoagulation services for the future

MEDICAL ASSISTANCE BULLETIN

V1: Draft Nov Making decisions... about anticoagulation for stroke prevention in atrial fibrillation.

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

New Oral Anticoagulants. How safe are they outside the trials?

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Clinical pathway concept - a key to seamless care

Safety indicators for inpatient and outpatient oral anticoagulant care

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Cardiovascular Subcommittee of PTAC Meeting held 27 February (minutes for web publishing)

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

The author has no disclosures

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

A PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF)

Novel OAC s : How should we use them?

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

GENERAL PRACTICE BASED PHARMACIST

Medicines reconciliation on admission and discharge from hospital policy April WHSCT medicines reconciliation policy 1

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

NOACs: Innovation in anticoagulation

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.

Atrial Fibrillation and Anticoagulants

Antiplatelet and Antithrombotics From clinical trials to guidelines

Updates to the Alberta Human Services Drug Benefit Supplement

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Medicines Optimisation Supporting information for the prototype dashboard

Submission by the Irish Pharmacy Union to the Department of Health on the Scope for Private Health Insurance to incorporate Additional Primary Care

Objectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant

Disclosure/Conflict of Interest

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation

Hertfordshire guidelines for oral anticoagulation of patients with non-valvular AF

Atrial Fibrillation Patient Survey Online survey of AFib Patients 65+ Exploring Experiences with the Diagnosis and Treatment of AFib.

The Role of the Newer Anticoagulants

} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF

New Anticoagulants: What to Use What to Avoid

Anticoagulation Therapy Update

East Kent Prescribing Group

One year on. Why are patients still having unnecessary AF-related strokes?

Breadth of indications matters One drug for multiple indications

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

- Understand Datamonitor's independent appraisal of marketed oral anticoagulant brands and key pipeline agents indicated for treating SPAF.

Alert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March Action for the NHS and the independent sector

Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013

Xarelto (Rivaroxaban)

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Pharmacists improving care in care homes

Brand Name Marevan Pradaxa Xarelto Eliquis

Transcription:

Breakfast symposium: From hospital to home - the focus on the patient Nadya Hamedi DARZI Fellow UCLPartners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee & Lynne Garforth Clinical Primary Care Pharmacist Ashburton Prescribing Consultants Delivered by:

This symposium has been organised and funded by Bayer HealthCare. Xarelto (rivaroxaban) prescribing information is available at this meeting from the Bayer stand. Adverse events should be reported Reporting forms and further information can be found at www.mhra.gov.uk/yellowcard adverse events should also be reported to Bayer : Tel.: 01635 563000 Fax.: 01635 563703 phdsguk@bayer.co.uk L.GB.04.2015.10788 Date: April 2015

From hospital to home- the focus on the patient Lynne Garforth Clinical Pharmacist Primary care Ashburton Prescribing Consultants Ltd Nadya Hamedi DARZI fellow Barts Heart Centre/UCLPartners

Declaration Funding / speaker fees received from Bayer, Pfizer / BMS, Daiichi- Sankyo, Boehringer Ingelheim

Overview What are the risks when a patient moves from the hospital setting back to their home? Who should support the patient? What are the common issues seen by primary care clinicians with a particular focus on the anticoagulated patient? Transferring patients back to the care of their anticoagulation clinic How can pharmacists reduce the risk? How can we improve adherence to anticoagulants? Making an impact on stroke prevention What are the educational needs of pharmacist

Primary care pharmacy GP practice support Medicines optimisation to support chronic disease management e.g AF reviews Medication reviews Management of repeat prescribing system Post discharge meds reconciliation Anticoagulation clinics Local health trusts GP practice level CCG projects Medication reviews in the vulnerable elderly

Medicines reconciliation Medicines reconciliation, as defined by the Institute for Healthcare Improvement, is the process of identifying an accurate list of a person's current medicines and comparing them with the current list in use, recognising any discrepancies, and documenting any changes, thereby resulting in a complete list of medicines, accurately communicated. But who is responsible for ensuring these changes reach the patient? Is it the HCP or does the patient need to be responsible for managing their own care?

Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes: NICE Guideline 5 Recognise that medicines reconciliation may need to be carried out on more than one occasion during a hospital stay for example, when the person is admitted, transferred between wards or discharged. In primary care, carry out medicines reconciliation for all people who have been discharged from hospital or another care setting. This should happen as soon as is practically possible, before a prescription or new supply of medicines is issued and within 1 week of the GP practice receiving the information. Organisations should ensure that medicines reconciliation is carried out by a trained and competent health professional ideally a pharmacist, pharmacy technician, nurse or doctor with the necessary knowledge, skills and expertise including: effective communication skills technical knowledge of processes for managing medicines therapeutic knowledge of medicines use. Involve patients and their family members or carers, where appropriate, in the medicines reconciliation process.

Medicines reconciliation within the GP practice Safe systems in place - protocols for repeat prescribing management TTO received Read coding Medications added / deleted Prescription issued when patient presents at practice Is this enough? Who is amending the medication lists Is the information clear? Is there a clinical check? Who is engaging with the patient?

What about the anticoagulation service? Often no information provided No follow up appointments Patient may have had Their warfarin stopped for a procedure Their dose changed Interacting drugs prescribed LMWH prescribed Warfarin stopped inappropriately

Safe systems can fail 84 year old lady discharged with a diagnosis of AF and started on rivaroxaban 15mg od Over 75 med review by pharmacist at the GP practice Medication had been added to the system as per TTO by GP Patient discharged with a supply of medication Dose was incorrect as CrCl 80ml/min clinical check had failed at several stages (hospital and by GP)

Patient engagement 77 year old housebound man discharged following an MI Ticagrelor started by hospital in addition to aspirin and other meds Meds updated by GP on clinical system as per TTO 6 weeks later pharmacist carried out med review and noticed all meds had been collected except those added during recent admission Patient not taking ticagrelor Community pharmacy had not received TTO Patient unaware Role of GP practice in communicating changes can be improved

The importance of clear instructions on TTO 80 year old lady on warfarin (AF) on admission to hospital Switched to a NOAC during admission NOAC listed on TTO Warfarin not on meds list on TTO but was not mentioned in comments where other meds that had been stopped had been But GP did not remove from repeat prescription Community Pharmacist intervened

Communicate with the anticoag service Patient attended usual anticoag appointment INR 1.3 On review, had been in hospital and had been discharged over a week ago on a lower dose than pre admission dose Common occurrence patients told to arrange own appointment, no direct communication with the service Can lead to increase risk especially where there have been dose changes to warfarin and / or interacting drugs added Could lead to patient being at risk for several months if appointment not imminent

Take every opportunity to counsel the patient 70 year old man with AF, admitted with TIA despite good INR control On discharge warfarin stopped and apixaban started Followed up as a result of missed appointment at anticoag service Was only taking apixaban once daily despite clear labelling Is this just a compliance issue or misunderstanding on behalf of patient?

Overcoming the issues Hospitals Improve communication to anticoagulation services Clear instruction as to what to do with EVERY medication patient was admitted on GP Practice Ensure clinical check happens as part of meds rec and challenge where necessary Improve communication channels to the hospitals, patients and community pharmacies Anticoagulation services Encourage patients to communicate med changes / details of hospital admissions etc Educate patients when switched to NOACs Develop interface and / or practice pharmacist roles

Improving adherence through good communication Establish the most effective way of communicating with each patient and, if necessary, consider ways of making information accessible and understandable (for example, using pictures, symbols, large print, different languages, an interpreter or a patient advocate). Encourage patients to ask about their condition and treatment. Ask patients open ended questions because these are more likely to uncover patients' concerns. Primary care has the benefit of frequent interactions with patients to support relationship building

PRESCRIBE by APC

PRESCRIBE by APC

Involve patients in the treatment decision Newly identified patients (new diagnosis or previously refused warfarin) Be clear about the risk of stroke and lack of benefit of aspirin Discuss modifiable bleeding risks Offer choice of all anticoagulants - Anticoagulation may be with apixaban, dabigatran etexilate, rivaroxaban or a vitamin K antagonist. NICE CG180 Medication won t work if a patient doesn t take it

Conclusion Keep the communication channels open Between HCPs in the different settings Between the HCP and the patient Review current systems such as repeat prescribing management Encourage CCGs to invest in pharmacist led meds reconciliation in primary care Take every opportunity to involve the patient, don t assume someone else has or that the patient has taken everything on board lynnegarforth@ashburtonprescribing.com

Pharmacist: Making an impact on stroke prevention Nadya Hamedi DARZI fellow Barts Health NHS Trust/UCLPartners

Declaration None Bayer sponsoring presentation

NICE guidelines for AF (2014) one of the key priorities: personalised package of care for patients support and education practical advice on anticoagulation

NICE guidelines for medicine adherence (2009) Enabling patients to make informed choices by involving and supporting them in decisions about prescribed medicines 1/3 to 1/2 of all medicines prescribed for long-term conditions 5% to 8% of unplanned hospital admissions are due to medication issues

NICE guidelines for medicine optimisation (2015) Medication review, based healthcare professionals knowledge and skills, including all of the following: Technical knowledge of processes for managing medicines Therapeutic knowledge on medicines use Effective communication skills.

Adherence to new medication for chronic conditions Effective treatments Patient Practitioner Optimum outcomes Caro JJ et al., CMAJ 1990, 160: 31-37. Barber et al., Qual Saf Health Care 2004;13:172 175.

New Medicine Service (NMS) Conditions Asthma and Chronic Obstructive Pulmonary Disease (COPD) Hypertension Type II diabetes 10% improvement in adherence Antiplatelet/ anticoagulant therapy The service offers patients support within the first 21 days of new medication initiation 1. Patient engagement 2. Intervention 3. Follow up

How can pharmacist make an impact on stroke prevention in patients with Atrial Fibrillation?

Opportunity for Pharmacists to support anticoagulation needs of patient with Atrial Fibrillation

Adherence programme Darzi fellow Referral from 1 o /2 o care Unmet need Capacity of anticoagulation clinics NMS/MURs Educational Needs Atrial fibrillation Anticoagulation CBT Referral Process direct to community pharmacy after NOAC Initiation Patient need Community pharmacy New medicines Evaluation of pathway redesign for patients & professionals

Resources and training on oral anticoagulants for pharmacist

Resources and training on oral anticoagulants for pharmacist

Summary Effective treatments Patient Practitioner Optimum outcomes Co-producing patient-centred approach

Interest in joining focus groups? Contact: Nadya Hamedi nadya.hamedi@bartshealth.nhs.uk Tel: 0203 465 6419